Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2006-02-14
2006-02-14
Crouch, Deborah (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C514S04400A, C435S320100
Reexamination Certificate
active
06998117
ABSTRACT:
Disclosed are methods and compositions for the selective manipulation of gene expression through the preparation of retroviral expression vectors for expressing antisense sequences, such as K-ras oncogene antisense sequences, or sequences encoding a desired product, such as wild type p53 sequences. Preferred retroviral vectors of the present invention incorporate the β-actin promoter in a reverse orientation with respect to retroviral transcription. Preferred antisense RNA constructs of the present invention employ the use of antisense intron DNA corresponding to distinct intron regions of the gene whose expression is targeted for down-regulation. In an exemplary embodiment, a human lung cancer cell line (NCI-H460a) with a homozygous spontaneous K-ras mutation was transfected with a recombinant plasmid that synthesizes a genomic segment of K-ras in antisense orientation. Translation of the mutated K-ras mRNA was specifically inhibited, whereas expression of H-ras and N-ras was unchanged. A three-fold growth inhibition occurred in H460a cells when expression of the mutated ras p21 protein was down-regulated by antisense RNA and cells remained viable. The growth of H460a tumors in nu
u mice was substantially reduced by expressed K-ras antisense RNA.
REFERENCES:
patent: 4920209 (1990-04-01), Davis et al.
patent: 5166320 (1992-11-01), Wu et al.
patent: 5252479 (1993-10-01), Srivastava
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5362623 (1994-11-01), Vogelstein et al.
patent: 5496731 (1996-03-01), Xu et al.
patent: 5527676 (1996-06-01), Vogelstein et al.
patent: 5532220 (1996-07-01), Lee et al.
patent: 5585362 (1996-12-01), Wilson et al.
patent: 5747469 (1998-05-01), Roth et al.
patent: 5932210 (1999-08-01), Gregory et al.
patent: 6090566 (2000-07-01), Vogelstein et al.
patent: 6800617 (2004-10-01), Vogelstein et al.
patent: 0475623 (1992-03-01), None
patent: 2688514 (1993-09-01), None
patent: 4-9338 (1992-01-01), None
patent: WO 90/05180 (1990-05-01), None
patent: WO 91/15580 (1991-10-01), None
patent: WO 93/03769 (1993-03-01), None
patent: WO 93/19191 (1993-09-01), None
patent: WO 93/25224 (1993-12-01), None
patent: WO 94/06910 (1994-03-01), None
patent: WO 94/08026 (1994-04-01), None
patent: WO 94/10323 (1994-05-01), None
patent: WO 94/18992 (1994-09-01), None
patent: WO 94/24297 (1994-10-01), None
patent: WO 94/26914 (1994-11-01), None
patent: WO 95/02697 (1995-01-01), None
patent: WO 95/11301 (1995-04-01), None
patent: 95/11984 (1995-05-01), None
patent: WO 95/14101 (1995-05-01), None
patent: WO 95/14102 (1995-05-01), None
patent: WO 95/23867 (1995-09-01), None
patent: WO 95/30002 (1995-11-01), None
Roth et al (1996) Nature Med. 2, 985-991.
Georges et al (1993) Canc. Res. 53, 1743-1746.
Santhanam et al., “Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product,”Proc. Natl. Acad. Sci. USA, 88:7605-7609, 1991.
Anderson, “Human Gene Therapy,”Nature, 392:25-30, Apr. 30, 1998.
Bacchetti, et al, “Inhibition of Cell Proliferation by and Adenovirus Vector Expressing the Human Wild Type p53 Protein,”International Journal of Oncology, 3:781-788, 1993.
Baker et al., “Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carinomas,”Science, 244:217-221, Apr. 1989.
Baker et al., “p53 Gene Mutations Occur in Combination with 17p Allelic Deletions as Late Events in Colorectal Tumorigenesis,”Cancer Research, 50:7717-7722, Dec. 1990.
Baker et al., “Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53,”Science, 249:912-915, Aug, 1990.
Bargonetti et al., “Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication,”Cell, 65:1083-1091, 1991.
Berkner, “Development of adenovirus vectors for the expression of heterologous genes”,BioTechniques, 6(7):616-629, 1988.
Blenis, “Signal transduction via the MAP kinases: Proceed at your own RSK”,Proc. Natl. Acad. Sci. USA, 90:5889-5892, 1993.
Brachman et al., “p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines”,Cancer Res., 53:3667-3669, 1993.
Brown et al., “Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines,”Int. J. Cancer, 55:678-684, 1993.
Brown et al., “Mutant p53 confers cisplatin-sensitivity to resistant ovarian tumour cells with elevated wild-type p53,”Proc. Am. Assoc. Cancer Res., 34:355, abstract #2116, 1993.
Cai et al., “Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer,”Hum. Gene. Ther., 4:617-24, 1993.
Capecchi, “Altering the genome by homologous recombination”,Science, 244:1288-1292, 1989.
Carter et al., “Adenovirus Containing a Deletion of the Early Region 2A Gene Allows Growth of Adeno-Associated Virus with Decreased Efficiency,”Virology, 191:473-476, 1992.
Chang et al., “Inhibition of intratracheal lung cancer development by systemic delivery of E1A,”Oncogene, 13:1405-1412, 1996.
Chang et al., “Restoration of the G1 Checkpoint and the Apoptotic Pathway Mediated by Wild-type p53 Sensitizes Squamous Cell Carcinoma of the Head and Neck to Radiotherapy,”Arch Otolaryngol Head Neck Surg., 123:507-512, 1997.
Cheng et al., “Suppression of acute lymphoblastic leukemia by the human wild-type p53 gene,”Cancer Res., 52:222-226, 1992.
Clarke, et al, “Thymocyte Apoptosis Induced by p53-Dependent and Independent Pathways,”Nature, 362:849-852, Apr. 29, 1993.
Coleman et al., “Radiation and chemotherapy sensitizers and protectors”,Critical Reviews In Oncology/Hematology, 10(Issue 3):225-252, 1990.
Colicos et al., Construction of a recombinant adenovirus containing the denV gene from bacteriophase T4 which can partially restore the DNA repair deficiency in xeroderma pigmentosum fibroblasts,Carcinogenesis, 12(2)249-255, 1991.
Comings, “A general theory of carcinogenesis,”Proc. Natl. Acad. Sci. USA, 70(12-Part I):3324-3328, 1973.
Culver et al., “Gene Therapy for Cancer,”TIG, 10(5):174-178, 1994.
Culver, et al, “In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors,”Science, 256:1550-1552, 1992.
Curiel et al., “High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes,”Human Gene Therapy, 3:147-154, 1992.
Davidson et al., “A model system for in vivo gene transfer into the central nervous system using adenoviral vector,”Nature Genetics, 3:219-223, 1993.
Diller et al., “p53 Functions as a Cell Cycle Control Protein in Osteosarcomas,”Molecular and Cellular Biology, 10(11):5772-5781, Nov. 1990.
Donehower, “Tumor suppressor gene p53 and apoptosis,”Cancer Bull., 46(2);161-166, 1994.
Dorigo et al., “Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function,”J. Neurosurg., 88:535-540, 1998.
Eaves et al., “The biology of normal and neoplastic stem cells in CML,” Chronic Myeloid Leukemia, 2ndInt'l Conference, Bologna, Italy, Oct. 4-7, 1992. FromLeukemia and Lymphoma, 11:245-253 (1993).
El Rouby et al., “p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression,”Blood, 82(11):3452-3459, 1993.
El-Deiry et al., “WAF1, a potential mediator of p53 tumor suppression,”Cell, 75:817-825, 1993.
Eliyahu et al., “Meth A Fibrosarcoma Cells Express Two Transforming Mutant p53 Species,”oncogene, 3:313-321, 1988.
Eliyahu et al., “Wild-type p53 Can Inhibit Oncogene-Mediated Focus Formation,”Proc. Nat. Acad. Sci. USA, 85:8763-8767, Nov. 1989.
Fan et al., “p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA dama
Mukhopadhyay Tapas
Roth Jack A.
Tainsky Michael A.
Board of Regents , The University of Texas System
Crouch Deborah
Fulbright & Jaworski LLP
LandOfFree
Cancer treatment with retroviral vectors comprising... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer treatment with retroviral vectors comprising..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer treatment with retroviral vectors comprising... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3706560